Brooke Hasson, PhD

Seres Therapeutics, Cambridge, MA

Disclosure(s): Seres Therapeutics: employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-127) Safety and Efficacy of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Patients with Recurrent Clostridioides difficile Infection (CDI): Subgroup Analysis by Number of Prior CDI Recurrences from an Integrated Analysis of Phase 3 Trials
  Thursday, October 17, 2024

  12:15 PM - 1:30 PM US PT